Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor xa

American Journal of Cardiovascular Drugs

Volumn 16, Issue 2, 2016, Pages 119-127

  Vakkalagadda, Blisse ^a   Frost, Charles ^a   Byon, Wonkyung ^b   Boyd, Rebecca A ^b   Wang, Jessie ^a   Zhang, Donglu ^a   Yu, Zhigang ^a   Dias, Clapton ^a   Shenker, Andrew ^a   LaCreta, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APIXABAN; ASPARTATE AMINOTRANSFERASE; RIFAMPICIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELIMINATION RATE CONSTANT; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NAUSEA AND VOMITING; NORMAL HUMAN; OPEN STUDY; ORAL CLEARANCE; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PYRAZOLES; PYRIDONES; RIFAMPIN; YOUNG ADULT;

EID: 84953404552     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-015-0157-9     Document Type: Article

References (41)

1. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50: 5339-56.
2. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6: 820-9.
3. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361: 594-604.
4. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363: 2487-98.
5. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375: 807-15.
6. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364: 806-17.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365: 981-92.
8. Agnelli G, Buller HR, Cohen, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369: 799-808.
9. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368: 699-708.
10. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76: 776-86.
11. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75: 476-87.
12. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]. J Clin Pharmacol. 2008;48: 1132.
13. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37: 74-81.
14. Wang L, He K, Maxwell B, et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos. 2011;39: 256-64.
15. Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41: 906-15.
16. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37: 1738-48.
17. Wang L, Raghavan N, He K, et al. Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos. 2009;37: 802-8.
18. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38: 448-58.
19. He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36: 129-39.
20. Zhang D, He K, Herbst JJ, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41: 827-35.
21. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9: 215-36.
22. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50(Suppl 1): S3-11.
23. Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79: 838-46.
24. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104: 147-53.
25. Sanofi-Aventis U.S. LLC. Rifadin (rifampin) package insert. 2013. http://products.sanofi.us/rifadin/Rifadin.pdf. Accessed 2 Feb 2015.
26. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90: 1871-8.
27. Pursley J, Shen JX, Schuster A, et al. LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis. 2014;6: 2071-82.
28. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci. 1982;71: 474-5.
29. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42: 819-50.
30. Kageyama M, Fukushima K, Togawa T, et al. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull. 2006;29: 779-84.
31. Yamada S, Uasui-Furukori N, Akamine Y, et al. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit. 2009;31: 764-8.
32. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14: 147-54.
33. Yamahira N, Frost C, Fukase H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther. 2014;52: 564-73.
34. Leil TA, Frost C, Wang X, Pfister M, LaCreta F. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacomet Syst Pharmacol. 2014;3: e136.
35. Frost CE, Song Y, Shenker A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015;54: 651-62.
36. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol. 2006;1: 5-20.
37. Food and Drug Administration. Guidance for industry. Drug interaction studies-study design, data analysis and implications for dosing and labeling: draft guidance. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf. Accessed 2 Feb 2015.
38. Backman JT, Kivistö KT, Olkkola KT, et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54: 53-8.
39. Link B, Haschke M, Grignaschi N, et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008;66: 473-84.
40. Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban tablets) Summary of product characteristics. 2013 May. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Infor mation/human/002148/WC500107728.pdf. Accessed 21 Aug 2015.
41. Bristol-Myers Squibb. Eliquis (apixaban tablets). Prescribing information. 2014 August. http://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/202155s009lbl.pdf. Accessed 21 Aug 2015.